The AbetaCs of Abeta-cleaving proteases.
The amyloid beta-protein (Abeta), which accumulates abnormally in Alzheimer disease (AD), is degraded by a diverse set of proteolytic enzymes. Abeta-cleaving proteases, largely ignored until only recently, are now known to play a pivotal role in the regulation of cerebral Abeta levels and amyloid plaque formation in animal models, and accumulating evidence suggests that defective Abeta proteolysis may be operative in many AD cases. This review summarizes the growing body of evidence supporting the involvement of specific Abeta-cleaving proteases in the etiology and potential treatment of AD. Recognition of the importance of Abeta degradation to the overall economy of Abeta has revised our thinking about the mechanistic basis of AD pathogenesis and identified a novel class of enzymes that may serve as both therapeutic targets and therapeutic agents.
Leissring
Malcolm A
MA
Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA. leissring@mayo.edu
D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000502:physiology*; D000818:Animals; D001921:Brain / Q000378:metabolism; D002478:Cells, Cultured; D003546:Cysteine Endopeptidases / Q000737:chemistry; D004721:Endoplasmic Reticulum / Q000378:metabolism; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D045726:Metalloproteases / Q000737:chemistry; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D017434:Protein Structure, Tertiary; D012697:Serine Endopeptidases / Q000737:chemistry; D015032:Zinc / Q000737:chemistry
D016229:Amyloid beta-Peptides; D045726:Metalloproteases; D012697:Serine Endopeptidases; D003546:Cysteine Endopeptidases; D015032:Zinc